---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-043561"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-08-21T23:59:59+00:00"
generated_at: "2026-06-11T06:28:40.349739+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics appoints EisnerAmper as new auditor after MHM resignation

## Summary
- EisnerAmper LLP engaged as independent auditor for FY 2023 and Q3 2023 review, effective Aug 18, 2023.
- Audit Committee and Board unanimously approved the engagement; no prior consultations with EisnerAmper occurred.
- MHM resigned as auditor on Aug 21, 2023, as previously reported on July 31, 2023.

## SEC filing metadata
- accession: 0000950170-23-043561
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-08-21T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 4.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017023043561/0000950170-23-043561-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017023043561/sabs-20230818.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-043561
- JSON: https://secwatch.observer/filing/0000950170-23-043561.json
- Plain text: https://secwatch.observer/filing/0000950170-23-043561.txt

## Key facts
- Auditor Changes
  SAB Biotherapeutics, Inc. engaged EisnerAmper LLP as its auditor.
  - Action: engagement
  - Auditor: EisnerAmper LLP
  source text: On August 18, 2023, SAB Biotherapeutics, Inc. (the "Company") engaged EisnerAmper LLP ("EisnerAmper") as the Company's independent public accounting firm
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017023043561/0000950170-23-043561-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.